Debiopharm International
Presence
Debiopharm Group has 3 subsidiaries including Après-demain, Debiopharm International and Debiopharm Research & Manufacturing.
They are in:
- Pharmaceuticals75%
- Biotechnology25%
Executives
View the org chart displaying its 23 main executives
Most searched biographies at Debiopharm International
- Bertrand Ducrey, Chief Executive Officer
- Thierry Mauvernay, Chairman of the Board
- Manuela Perraudin, Human Resources Director
Create your alert
to follow the executive moves at Debiopharm International.
Pharmaceuticals
Debiopharm Group has 1,863 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
- Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Debiopharm International
- Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-Driven Solid Tumors - Debiopharm
- Debiopharm to showcase research results of their DDR Inhibitors at the 2024 AACR Conference in San Diego - Debiopharm
- Strategikon Closes Series A1 Funding Round to Modernize Clinical Trials Business Operations Worldwide - Debiopharm
- Challenge pour la Qualité de vie du patient 2024, l’appel à projets est ouvert - Debiopharm
- Press Releases - Debiopharm
- TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer - Debiopharm
- Genialis and Debiopharm Set Up Biomarker Discovery Collaboration - Debiopharm
- Debiopharm Extends SunRock Biopharma Partnership for Antibody-Drug Conjugates Targeting HER3 in EGFR Mutated Cancers - Debiopharm
- Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer - Debiopharm
- MedaSystems Secures Additional Funding from Debiopharm Innovation Fund to Accelerate Global Access to Pre-approval Treatment - Debiopharm
- View more press releases Close
Social media about Debiopharm International
- Debiopharm International on Wikipedia, Google News & Yahoo Finance
- Debiopharm International on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Bertrand Ducrey 
Call Debiopharm International at +41 21...
